In the study, escalating doses of rC3-1 were delivered directly to the pulmonary artery of non-human primates. The lung is considered to be the target organ for potential toxicity.
All doses recorded no clinically significant changes in direct systemic blood pressure, pulmonary arterial pressure, lung resistance and dynamic compliance, respiratory rate, tidal volume and airway pressure.
InCode’s rC3-1 is being developed for the treatment of the rare chronic blood disease paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration. InCode plans to begin PNH clinical trials in the near future.